✓
Open
14 May 2025
✓
Close
16 May 2025
3
Allotment
—
✓
Listing
Wed, May 21, 2025
Price Band
₹96 to ₹101
Issue Size
29,46,000 shares (agg. up to ₹30 Cr)
Lot Size
1,200 Shares
Listing Date
Wed, May 21, 2025
Latest GMP
₹0
Est. Gain
0%
✦ AI Insight
GMP Trend
21-05-2025₹0Est. ₹101+0%
20-05-2025₹0Est. ₹101+0%
19-05-2025₹0Est. ₹101+0%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 6.47x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 39.99 | 27.05 | 20.58 | 17.74 |
| Total Income | 35.75 | 33.94 | 29.53 | 22.58 |
| Profit After Tax | 5.24 | 3.88 | 0.10 | 0.08 |
| NET Worth | 13.58 | 5.35 | 3.84 | 3.08 |
| Reserves and Surplus | 5.41 | 1.35 | ||
| Total Borrowing | 13.79 | 13.48 | 8.47 | 7.61 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Amwill Health Care Ltd. | SME | ₹59.98 Cr | ₹111 | 13.81 | ₹93.25 | -15.99% | ₹43.51 |
| Sat Kartar Shopping Ltd. | SME | ₹33.80 Cr | ₹81 | 14.87 | ₹161.55 | +99.44% | ₹117.00 |
| Onyx Biotec Ltd. | SME | ₹29.34 Cr | ₹61 | 26.81 | ₹56.75 | -6.97% | ₹37.55 |
| Medicamen Organics Ltd. | SME | ₹10.54 Cr | ₹34 | 30.53 | ₹144.70 | +325.59% | ₹26.50 |
| Quest Laboratories Ltd. | SME | ₹43.16 Cr | ₹97 | 23.03 | ₹147.35 | +51.91% | ₹82.00 |
| Senores Pharmaceuticals Ltd. | Mainboard | ₹582.11 Cr | ₹391 | 39.77 | ₹557.80 | +42.66% | ₹1,509.80 |
| Sai Life Sciences Ltd. | Mainboard | ₹3,042.62 Cr | ₹549 | 126.42 | ₹764.65 | +39.28% | ₹1,647.10 |
| Akums Drugs & Pharmaceuticals Ltd. | Mainboard | ₹1,856.74 Cr | ₹679 | null | ₹796.25 | +17.27% | ₹736.60 |
| Emcure Pharmaceuticals Ltd. | Mainboard | ₹1,952.03 Cr | ₹1008 | 34.55 | ₹1,359.15 | +34.84% | ₹1,925.80 |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capital expenditure towards purchase of new equipment/ machineries, etc. | 2.70 |
| 2 | Capital expenditure towards upgradation of existing manufacturing facility | 4.66 |
| 3 | Repayment/prepayme nt of certain borrowings availed by the Company | 0.99 |
| 4 | Funding working capital requirements of the Company | 14.68 |
| 5 | General Corporate Purposes | 4.43 |
| 6 | Issue Expenses | 2.30 |
| Total | 29.75 |
About Accretion Pharmaceuticals IPO
Updated on Aug 5, 2026
Contact Details
Accretion Pharmaceuticals Ltd. Address29 Xcelon Ind Park 1B/h, Intas Pharmaceuticals, Vasna ChacharvadSanandAhmedabad, Gujarat, 382213+91-97148 82929compliance@accretionpharma.comVisit Website